News

28 May 2013
TAL-effector nuclease: The USPTO issues a third patent licensed to Cellectis
Cellectis (NYSE PA: ALCLS), the global genome engineering specialist, announces the issuance by the USPTO on May 28, 2013 of a 3rd US patent (US 8,450,471) directed to TAL-...
21 May 2013
Compact TALEN™: the next generation of TAL effector nucleases
Cellectis (NYSE PA: ALCLS), the global genome engineering specialist, announced today that the high-impact scientific journal Nature Communications has published an in-house study...
16 May 2013
TAL-effector nuclease: Issuance by the USPTO of Two New Patents - Cellectis provides its customers TALEN™ product under license of these patents to easily achieve any genome engineering projects.
New Brighton, May 16, 2013 – Cellectis (NYSE PA: ALCLS), the global genome engineering specialist, announced the issuance by the USPTO on May 14th, 2013 of two new US...
Copyright 2012 Cellectis
Design & Development by EtonDigital